RESUMO
BACKGROUND: Drug-coated balloons (DCBs) have shown promise in improving the outcomes for patients with peripheral artery disease. We compared a paclitaxel-coated balloon with percutaneous transluminal angioplasty (PTA) for the treatment of symptomatic superficial femoral and popliteal artery disease. METHODS AND RESULTS: The IN.PACT SFA Trial is a prospective, multicenter, single-blinded, randomized trial in which 331 patients with intermittent claudication or ischemic rest pain attributable to superficial femoral and popliteal peripheral artery disease were randomly assigned in a 2:1 ratio to treatment with DCB or PTA. The primary efficacy end point was primary patency, defined as freedom from restenosis or clinically driven target lesion revascularization at 12 months. Baseline characteristics were similar between the 2 groups. Mean lesion length and the percentage of total occlusions for the DCB and PTA arms were 8.94 ± 4.89 and 8.81 ± 5.12 cm (P=0.82) and 25.8% and 19.5% (P=0.22), respectively. DCB resulted in higher primary patency versus PTA (82.2% versus 52.4%; P<0.001). The rate of clinically driven target lesion revascularization was 2.4% in the DCB arm in comparison with 20.6% in the PTA arm (P<0.001). There was a low rate of vessel thrombosis in both arms (1.4% after DCB and 3.7% after PTA [P=0.10]). There were no device- or procedure-related deaths and no major amputations. CONCLUSIONS: In this prospective, multicenter, randomized trial, DCB was superior to PTA and had a favorable safety profile for the treatment of patients with symptomatic femoropopliteal peripheral artery disease. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique Identifiers: NCT01175850 and NCT01566461.
Assuntos
Angioplastia/métodos , Angioplastia/tendências , Artéria Femoral , Doença Arterial Periférica/terapia , Artéria Poplítea , Dispositivos de Acesso Vascular/tendências , Idoso , Angioplastia com Balão/métodos , Angioplastia com Balão/tendências , Feminino , Artéria Femoral/patologia , Humanos , Internacionalidade , Masculino , Pessoa de Meia-Idade , Doença Arterial Periférica/diagnóstico , Artéria Poplítea/patologia , Estudos Prospectivos , Método Simples-Cego , Fatores de Tempo , Resultado do TratamentoRESUMO
BACKGROUND: Sirolimus-eluting stents reduce rates of restenosis and reintervention, as compared with uncoated stents. Data are limited regarding the safety and efficacy of such stents in primary percutaneous coronary intervention (PCI) for acute myocardial infarction with ST-segment elevation. METHODS: We performed a single-blind, multicenter, prospectively randomized trial to compare sirolimus-eluting stents with uncoated stents in primary PCI for acute myocardial infarction with ST-segment elevation. The trial included 712 patients at 48 medical centers. The primary end point was target-vessel failure at 1 year after the procedure, defined as target-vessel-related death, recurrent myocardial infarction, or target-vessel revascularization. A follow-up angiographic substudy was performed at 8 months among 174 patients from selected centers. RESULTS: The rate of the primary end point was significantly lower in the sirolimus-stent group than in the uncoated-stent group (7.3% vs. 14.3%, P=0.004). This reduction was driven by a decrease in the rate of target-vessel revascularization (5.6% and 13.4%, respectively; P<0.001). There was no significant difference between the two groups in the rate of death (2.3% and 2.2%, respectively; P=1.00), reinfarction (1.1% and 1.4%, respectively; P=1.00), or stent thrombosis (3.4% and 3.6%, respectively; P=1.00). The degree of neointimal proliferation, as assessed by the mean (+/-SD) in-stent late luminal loss, was significantly lower in the sirolimus-stent group (0.14+/-0.49 mm, vs. 0.83+/-0.52 mm in the uncoated stent group; P<0.001). CONCLUSIONS: Among selected patients with acute myocardial infarction, the use of sirolimus-eluting stents significantly reduced the rate of target-vessel revascularization at 1 year. (ClinicalTrials.gov number, NCT00232830 [ClinicalTrials.gov].).
Assuntos
Angioplastia Coronária com Balão , Imunossupressores/administração & dosagem , Infarto do Miocárdio/terapia , Sirolimo/administração & dosagem , Stents , Terapia Combinada , Angiografia Coronária , Ponte de Artéria Coronária , Intervalo Livre de Doença , Feminino , Seguimentos , Humanos , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Infarto do Miocárdio/mortalidade , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/antagonistas & inibidores , Prevenção Secundária , Método Simples-Cego , Trombose/epidemiologia , Grau de Desobstrução VascularRESUMO
BACKGROUND: Carotid endarterectomy is more effective than medical management in the prevention of stroke in patients with severe symptomatic or asymptomatic atherosclerotic carotid-artery stenosis. Stenting with the use of an emboli-protection device is a less invasive revascularization strategy than endarterectomy in carotid-artery disease. METHODS: We conducted a randomized trial comparing carotid-artery stenting with the use of an emboli-protection device to endarterectomy in 334 patients with coexisting conditions that potentially increased the risk posed by endarterectomy and who had either a symptomatic carotid-artery stenosis of at least 50 percent of the luminal diameter or an asymptomatic stenosis of at least 80 percent. The primary end point of the study was the cumulative incidence of a major cardiovascular event at 1 year--a composite of death, stroke, or myocardial infarction within 30 days after the intervention or death or ipsilateral stroke between 31 days and 1 year. The study was designed to test the hypothesis that the less invasive strategy, stenting, was not inferior to endarterectomy. RESULTS: The primary end point occurred in 20 patients randomly assigned to undergo carotid-artery stenting with an emboli-protection device (cumulative incidence, 12.2 percent) and in 32 patients randomly assigned to undergo endarterectomy (cumulative incidence, 20.1 percent; absolute difference, -7.9 percentage points; 95 percent confidence interval, -16.4 to 0.7 percentage points; P=0.004 for noninferiority, and P=0.053 for superiority). At one year, carotid revascularization was repeated in fewer patients who had received stents than in those who had undergone endarterectomy (cumulative incidence, 0.6 percent vs. 4.3 percent; P=0.04). CONCLUSIONS: Among patients with severe carotid-artery stenosis and coexisting conditions, carotid stenting with the use of an emboli-protection device is not inferior to carotid endarterectomy.
Assuntos
Estenose das Carótidas/terapia , Endarterectomia das Carótidas , Stents , Adulto , Idoso , Idoso de 80 Anos ou mais , Angioplastia com Balão/instrumentação , Estenose das Carótidas/mortalidade , Estenose das Carótidas/cirurgia , Comorbidade , Intervalo Livre de Doença , Embolia/prevenção & controle , Embolia/terapia , Desenho de Equipamento , Humanos , Incidência , Pessoa de Meia-Idade , Infarto do Miocárdio/prevenção & controle , Fatores de Risco , Acidente Vascular Cerebral/prevenção & controleRESUMO
Although generalized equations to predict body composition exist, the validity of these equations when applied to a homogeneous group of athletic women is uncertain. Sixty-five women runners (age = 28.3 ± 6.4 yrs; ht = 166.8 ± 6.2 cm; wt = 58.9 ± 6.6 kg; body density (Db ) = 1.047 ± 0.009 g · cc-1 ; percentage body fat (%BF) = 22.1 ± 3.7%; VÌO2 max = 56.0 ± 5.3 ml/kg · min-1 ; training volume = 45.8 ± 16.0 km · wk-1 ) were used to cross-validate the Jackson, Pollock, and Ward (1980) generalized quadratic skinfold equations (JPW) and the Tran and Weltman (1989) generalized girth equation (TW). Additionally, the average of TW and the JPW quadratic skinfold equations were calculated and compared to hydrostatic weighing (HW). None of the JPW equations nor the TW equation accurately predicted Db (P <0.05). All JPW equations underpredicted %BF with values ranging from 16.3-19.7%. Correlations ranged from r = 0.73 to r = 0.79. Standard errors (SE = [∑(Y - Y')2 /N]1/2 ) for predicting %BF ranged from 6.6% to 3.9%. The TW equation underestimated body density (1.041 ± 0.008) with a correlation of r = 0.54 and a SE of 4.2%. When the results of the JPW sum of 4 skinfolds (or the sum of 7 skinfolds) was averaged with TW, no significant mean differences in Db or %BF were observed and the standard errors were 2.7%. Additionally, a population specific equation was derived using skinfolds and girths (n = 40) and was shown to accurately predict body density in a cross-validation sample of women runners (n = 25). This equation yielded a correlation of r = 0.72 and a SE = 2.7%. It was concluded that the combination of skinfold and girth techniques is superior to either method alone when predicting body composition in women runners. © 1993 Wiley-Liss, Inc.
RESUMO
BACKGROUND: Drug-eluting balloons (DEB) may reduce infrapopliteal restenosis and reintervention rates versus percutaneous transluminal angioplasty (PTA) and improve wound healing/limb preservation. OBJECTIVES: The goal of this clinical trial was to assess the efficacy and safety of IN.PACT Amphirion drug-eluting balloons (IA-DEB) compared to PTA for infrapopliteal arterial revascularization in patients with critical limb ischemia (CLI). METHODS: Within a prospective, multicenter, randomized, controlled trial with independent clinical event adjudication and angiographic and wound core laboratories 358 CLI patients were randomized 2:1 to IA-DEB or PTA. The 2 coprimary efficacy endpoints through 12 months were clinically driven target lesion revascularization (CD-TLR) and late lumen loss (LLL). The primary safety endpoint through 6 months was a composite of all-cause mortality, major amputation, and CD-TLR. RESULTS: Clinical characteristics were similar between the 2 groups. Significant baseline differences between the IA-DEB and PTA arms included mean lesion length (10.2 cm vs. 12.9 cm; p = 0.002), impaired inflow (40.7% vs. 28.8%; p = 0.035), and previous target limb revascularization (32.2% vs. 21.8%; p = 0.047). Primary efficacy results of IA-DEB versus PTA were CD-TLR of 9.2% versus 13.1% (p = 0.291) and LLL of 0.61 ± 0.78 mm versus 0.62 ± 0.78 mm (p = 0.950). Primary safety endpoints were 17.7% versus 15.8% (p = 0.021) and met the noninferiority hypothesis. A safety signal driven by major amputations through 12 months was observed in the IA-DEB arm versus the PTA arm (8.8% vs. 3.6%; p = 0.080). CONCLUSIONS: In patients with CLI, IA-DEB had comparable efficacy to PTA. While primary safety was met, there was a trend towards an increased major amputation rate through 12 months compared to PTA. (Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia [INPACT-DEEP]; NCT00941733).